S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
66,000% upside on tiny biotech? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
66,000% upside on tiny biotech? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
66,000% upside on tiny biotech? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
66,000% upside on tiny biotech? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NYSE:ENOV

Enovis (ENOV) Stock Forecast, Price & News

$55.38
-0.01 (-0.02%)
(As of 06/6/2023 ET)
Compare
Today's Range
$55.01
$55.68
50-Day Range
$52.19
$58.71
52-Week Range
$43.88
$67.32
Volume
463,773 shs
Average Volume
417,406 shs
Market Capitalization
$3.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.88

Enovis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Healthy
3.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Enovis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$954,181 Sold Last Quarter
Proj. Earnings Growth
22.03%
From $2.27 to $2.77 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

112th out of 981 stocks

Surgical Appliances & Supplies Industry

6th out of 18 stocks


ENOV stock logo

About Enovis (NYSE:ENOV) Stock

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Stock News Headlines

WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Enovis Co. (NYSE:ENOV) Short Interest Update
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Robert W. Baird Keeps Their Buy Rating on Enovis (ENOV)
Q1 2023 Enovis Corp Earnings Call
Enovis: Q1 Earnings Insights
Enovis Announces First Quarter 2023 Results
Earnings Outlook For Enovis
Enovis (ENOV) to Release Earnings on Thursday
See More Headlines

ENOV Price History

ENOV Company Calendar

Last Earnings
5/04/2023
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+17.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
0 Analysts

Profitability

Net Income
$-13,290,000.00
Pretax Margin
0.36%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$6.24 per share
Book Value
$63.71 per share

Miscellaneous

Free Float
51,717,000
Market Cap
$3.02 billion
Optionable
Optionable
Beta
2.02

Key Executives

  • Mr. Mitchell P. Rales (Age 65)
    Co-Founder & Independent Chairman
    Comp: $1
  • Mr. Matthew L. Trerotola (Age 55)
    CEO & Director
    Comp: $3.48M
  • Mr. Brady R. Shirley (Age 56)
    Pres, COO & Director
    Comp: $1.68M
  • Mr. Christopher M. Hix (Age 60)
    Exec. VP of Fin. & CFO
    Comp: $1.39M
  • Mr. Daniel A. Pryor (Age 54)
    Exec. VP of Strategy & Bus. Devel.
    Comp: $1.27M
  • Mr. John Kleckner (Age 45)
    Principal Accounting Officer
  • Mr. Michael S. Macek (Age 50)
    VP of Fin. & Investor Relations
  • Mr. Bradley J. Tandy (Age 63)
    Sr. VP & Gen. Counsel
  • Katie Sweet
    VP of Corp. Communication
  • Ms. Patricia A. Lang (Age 63)
    Sr. VP & Chief HR Officer













ENOV Stock - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ENOV shares.
View ENOV analyst ratings
or view top-rated stocks.

What is Enovis' stock price forecast for 2023?

0 brokers have issued 1-year price targets for Enovis' shares. Their ENOV share price forecasts range from $10,000,000.00 to $0.00. On average, they predict the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ENOV
or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2023?

Enovis' stock was trading at $53.52 at the start of the year. Since then, ENOV stock has increased by 3.5% and is now trading at $55.38.
View the best growth stocks for 2023 here
.

Are investors shorting Enovis?

Enovis saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,810,000 shares, a decrease of 6.7% from the April 30th total of 1,940,000 shares. Based on an average daily volume of 481,900 shares, the short-interest ratio is currently 3.8 days. Approximately 3.7% of the shares of the company are short sold.
View Enovis' Short Interest
.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ENOV earnings forecast
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) released its quarterly earnings results on Thursday, May, 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $406.20 million for the quarter, compared to analysts' expectations of $389.95 million. Enovis had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 3.24%. The company's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.37 earnings per share.

What guidance has Enovis issued on next quarter's earnings?

Enovis updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.18-$2.32 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of -.

What is Enovis' stock symbol?

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Who are Enovis' major shareholders?

Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.49%), Dimensional Fund Advisors LP (5.32%), Diamond Hill Capital Management Inc. (3.97%), Thrivent Financial for Lutherans (2.86%), State Street Corp (2.70%) and Channing Capital Management LLC (2.54%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends
.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enovis' stock price today?

One share of ENOV stock can currently be purchased for approximately $55.38.

How much money does Enovis make?

Enovis (NYSE:ENOV) has a market capitalization of $3.02 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

How many employees does Enovis have?

The company employs 6,800 workers across the globe.

How can I contact Enovis?

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.

This page (NYSE:ENOV) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -